Page 86 - 77_04

J.
M.
ZAPICO

y
col.

8.
Binker,
M.G.,
&
al.
(2009).
EGF
promotes
invasion
by
PANC-­-1
cells
through
Racl/ROS-­-
dependent

secretion
and
activation
of
MMP-­-2.
Biochemical
and
Biophysical
Research
Communications,

379(2),
445-­-450.

9.
Overall,
C.M.,
&
O.
Kleifeld
(2006).
Tumour
microenvironment
-­-
Opinion
-­-
Validating
matrix

metalloproteinases
as
drug
targets
and
anti-­-targets
for
cancer
therapy.
Nature
Reviews
Cancer,

6(3),
227-­-239.

10.
Xi,
L.,
&
al.
(2009).
A
combined
molecular
modeling
study
on
gelatinases
and
their
potent

inhibitors.
Journal
of
Computational
Chemistry,
31(1),
24-­-42.

11.
Summers,
J.B.
(1998).
in
Annual
Reports
in
Medicinal
Chemistry,
33,
D.
Robertson
and
J.

Plattner,
Editors,
Academic
Press:
San
Diego,
131-­-149.

12.
Terp,
G.E.,
&
al.
(2000).
Structural
differences
of
matrix
metalloproteinases.
Homology

modeling
and
energy
minimization
of
enzyme-­-substrate
complexes.
Journal
of
Biomolecular

Structure
&
Dynamics,
17(6),
933-­-946.

13.
Bode,
W.,
&
al.
(1999).
Structural
properties
of
matrix
metalloproteinases.
Cellular
and

Molecular
Life
Sciences:
CMLS,
55(4),
639-­-652.

14.
Natchus,
M.G.,
&
al.
(2000).
Development
of
new
hydroxamate
matrix
metalloproteinase

inhibitors
derived
from
functionalized
4-­-aminoprolines.
Journal
of
Medicinal
Chemistry,

43(26),
4948-­-63.

15.
Scozzafava,
A.,
&
al.
(2000).
Protease
inhibitors:
Synthesis
of
potent
bacterial
collagenase
and

matrix
metalloproteinase
inhibitors
incorporating
N-­-4-­-
nitrobenzylsulfonylglycine

hydroxamate
moieties.
Journal
of
Medicinal
Chemistry,
43(9),
1858-­-1865.

16.
Almstead,
N.G.,
&
al.
(1999).
Design,
synthesis,
and
biological
evaluation
of
potent
thiazine-­-
and

thiazepine-­-based
matrix
metalloproteinase
inhibitors.
Journal
of
Medicinal
Chemistry,
42(22),

4547-­-4562.

17.
Pikul,
S.,
&
al.
(1998).
Discovery
of
potent,
achiral
matrix
metalloproteinase
inhibitors.
Journal

of
Medicinal
Chemistry,
41(19),
3568-­-71.

18.
Kessenbrock.,
K,
&
al.
(2010).
Matrix
Metalloproteinases:
Regulators
of
the
Tumor

Microenvironment.
Cell,
141(1),
52-­-67.

19.
Tuccinardi,
T.,
&
al.
(2006).
Amber
force
field
implementation,
molecular
modelling
study,

synthesis
and
MMP-­-1/MMP-­-2
inhibition
profile
of
(R)
and
(S)-­-N-­-hydroxy-­-2-­-(N-­-

isopropoxybiphenyl-­-4-­-ylsulfonamido)-­-3-­-methylbutanamid
es.
Bioorganic
&
Medicinal

Chemistry,
14(12),
4260-­-4276.

20.
Martin,
M.D.,
&
al.
(2007).
The
other
side
of
MMPs:
Protective
roles
in
tumor
progression.

Cancer
and
Metastasis
Reviews,
26(3-­-4),
717-­-724.

21.
Almholt,
K.,
&
al.
(2008).
Metastasis
is
strongly
reduced
by
the
matrix
metalloproteinase

inhibitor
Galardin
in
the
MMTV-­-PymT
transgenic
breast
cancer
model.
Molecular
Cancer

Therapeutics,
7(9),
2758-­-2767.

22.
Dashevsky.,
O,
&
al.
(2009).
Platelet-­-derived
microparticles
promote
invasiveness
of
prostate

cancer
cells
via
upregulation
of
MMP-­-2
production.
International
Journal
of
Cancer,
124(8),

1773-­-1777.

23.
Pfaffen,
S.,
&
al.
(2010).
Isolation
and
characterization
of
human
monoclonal
antibodies
specific

to
MMP-­-1A,
MMP-­-2
and
MMP-­-3.
Experimental
Cell
Research,
316(5),
836-­-847.

24.
Whittaker.,
M,
&
al.
(1999).
Design
and
therapeutic
application
of
matrix
metalloproteinase

inhibitors.
Chemical
Reviews,
99(9),
2735-­-2776.

25.
Becker,
D.,
&
al.
(2005).
Synthesis
and
structure-­-activity
relationships
of
beta-­-
and
alpha-­-

piperidine
sulfone
hydroxamic
acid
matrix
metalloproteinase
inhibitors
with
oral
antitumor

efficacy.
Journal
of
Medicinal
Chemistry,
48(21),
6713-­-6730.

116